drugset
drugset / Trial / NCT00921336

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

NCT00921336 ↗

Phase 1 Completed 13 enrolled Kyowa Kirin, Inc. Kyowa Hakko Kirin Pharma, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will determine the maximum dose of KW-2450 that can be administered safely to subjects with advanced previously treated solid tumor and evaluate its effectiveness.

Timeline

Start
2009-06
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject KW-2450 Small molecule 800 mg Oral

Indications

cancer